Health systems cannot afford fragmented specialty care or missed downstream opportunity.
Three years ago, St. Luke's University Health Network made a deliberate decision to invest in precision medicine as a core enterprise priority. Through its DNA Answers program, the health system aligned clinical innovation with market strategy.
In this session, St. Luke's leaders share how they moved from vision to execution and why timing, partnership structure and executive alignment made the difference.
Insights include:
- The business case that elevated precision medicine to a board-level priority
- How St. Luke's structured its partnership to move faster and avoid adoption barriers
- The cultural shift sparked by patient stories and executive sponsorship
.jpg?width=120&height=120&name=Newman%20(1).jpg)